Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2013

Conditions
Glioblastoma Multiforme
Interventions
BIOLOGICAL

Autologous Dendritic Cell

Vaccine given by cervical lymph node injection 3 times every other week

DRUG

Temozolomide

Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC

PROCEDURE

Radiotherapy

RT is standard of care (SOC) post surgery

BIOLOGICAL

Dendritic Cell Vaccine

Vaccine given cervical lymphnode injection 3 times every other week

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00323115 - Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter